Increase of in vivo antitumoral activity by CD40L (CD154) gene transfer into pancreatic tumor cell-dendritic cell hybrids

Pancreas

Volumn 38, Issue 7, 2009, Pages 758-765

  Ziske, Carsten ^a   Etzrodt, Patricia E ^a   Eliu, Alex S ^a   Gorschlüter, Marcus ^a   Strehl, John ^a   Flieger, Dimitri ^b   Messmer, Davorka ^c   Schmitz, Volker ^a   Gonzalez Carmona, Maria A ^a   Sievers, Elisabeth ^a   Brossart, Peter ^a   Sauerbruch, Tilman ^a   Schmidt Wolf, Ingo G H ^a  

^a UNIVERSITY OF BONN   (Germany)

^b Gesundheits und Pflegezentrum Russelsheim   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CD154 (CD40L); Dendritic cell; Hybrids; Pancreatic cancer; Vaccination

Indexed keywords

B7 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; CHROMIUM 51; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; TUMOR VACCINE;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGENICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENE TRANSFER; GENETIC TRANSFECTION; HYBRID CELL; IMMUNE RESPONSE; LIVER METASTASIS; MALE; MOLECULE; MOUSE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME; TUMOR CELL; TUMOR VOLUME; ULTRASOUND; VACCINATION;

ANIMALS; CD40 LIGAND; CELL LINE, TUMOR; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; HYBRID CELLS; IMMUNOTHERAPY, ADOPTIVE; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

EID: 70349909660     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181ae5e1a     Document Type: Article

References (39)

1. Ahlgren JD. Chemotherapy for pancreatic carcinoma. Cancer. 1996;78:654-663.
2. Kelly DM, Benjamin IS. Pancreatic carcinoma. Ann Oncol. 1995;6:19-28.
3. Kato K, Cantwell MJ, Sharma S, et al. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest. 1998;101:1133-1141. (Pubitemid 28125292)
4. Xu Y, Song G. The role of CD40-CD154 interaction in cell immunoregulation. J Biomed Sci. 2004;11(4):426-438. (Pubitemid 38721026)
5. Schneider C, Schmidt T, Ziske C, et al. Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model. Gut. 2004;53:355-361. (Pubitemid 38241329)
6. Schmidt T, Ziske C, Märten A, et al. Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model. Cancer Res. 2003;63: 8962-8967. (Pubitemid 38064077)
7. Corbett TH, Roberts BJ, Leopold WR, et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res. 1984;44:717-726.
8. Priebe TS, Atkinson EN, Pan BF, et al. Intrinsic resistance to anticancer agents in the murine pancreatic adenocarcinoma PANC02. Cancer Chemother Pharmacol. 1992;29:485-489.
9. Meziane el K, Bhattacharyya T, Armstrong AC, et al. Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma. Int J Cancer. 2004;111(6):910-920.
10. Dallal RM, Christtakos P, Lee K, et al. Paucity of dendritic cells in pancreatic cancer. Surgery (St. Louis). 2002;131:135-138. (Pubitemid 34169537)
11. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;9:271-296.
12. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
13. Celluzzi CM, Falo LD Jr. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J Immunol. 1998;160:3081-3085.
14. Albert ML, Jegathesan M, Darnell RB. Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat Immunol. 2001;2:1010-1017. (Pubitemid 33069495)
15. Savai R, Schermuly RT, Pullamsetti SS, et al. A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells. Cancer Res. 2007;67(11): 5443-5453. (Pubitemid 46997285)
16. Lindner M, Schirrmacher V. Tumour cell-dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylen-glycol versus electro-fusion protocols. Eur J Clin Invest. 2002;32(3):207-217. (Pubitemid 36216606)
17. Wang J, Saffold S, Cao X, et al. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol. 1998;161(10):5516-5524. (Pubitemid 28519115)
18. Shurin MR, Yurkovetsky ZR, Tourkova IL, et al. Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumor-derived IL-10. Int J Cancer. 2002;101(1):61-68.
19. Tong Y, Song W, Crystal RG. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res. 2001;61:7530-7535. (Pubitemid 32995044)
20. Nakano T, Oka K, Takahashi T, et al. Roles of Langerhans' cells and T-lymphocytes infiltrating cancer tissues in patients treated by radiation therapy for cervical cancer. Cancer. 1992;70:2839-2844.
21. Tsujitani S, Okamura T, Baba H, et al. Endoscopic intratumoral injection of OK-432 and Langerhans' cells in patients with gastric carcinoma. Cancer. 1988;61:1749-1753. (Pubitemid 18112750)
22. Chen HW, Huang HI, Lee YP, et al. Linkage of CD40L to a self-tumor antigen enhances the antitumor immune responses of dendritic cell-based treatment. Cancer Immunol Immunother. 2002;51: 341-348.
23. Lefterova P, Marten A, Buttgereit P, et al. Induction of apoptosis in B lymphoma cells by activation with CD40L. Acta Haematol. 2000;103:168-171.
24. Enk AH, Angeloni VL, Udey MC, et al. Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance. J Immunol. 1993;151:2390-2398. (Pubitemid 23264491)
25. Brossart P, Zobywalski A, Grunebach F, et al. Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells. Cancer Res. 2000;60:4485-4492. (Pubitemid 32103629)
26. Schmitz V, Barajas M, Wang L, et al. Adenovirus-mediated CD40 ligand gene therapy in a rat model of orthotopic hepatocellular carcinoma. Hepatology. 2001;34:72-81. (Pubitemid 32591485)
27. Banchereau J, Bazan F, Blanchard D, et al. The CD40 antigen and its ligand. Annu Rev Immunol. 1994;12:881-922.
28. Wierda WG, Cantwell MJ, Woods SJ, et al. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood. 2000;96: 2917-2924. (Pubitemid 30815196)
29. Serhal K, Baillou C, Ghinea N, et al. Characteristics of hybrid cells obtained by dendritic cell/tumour cell fusion in a T-47D breast cancer cell line model indicate their potential as anti-tumour vaccines. Int J Oncol. 2007;31(6):1357-1365.
30. Zhu HC, Wu SH, Huang BY, et al. Activation of anti-tumor cytotoxic T lymphocytes by fusion of human dendritic cells and melanoma cells. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2008;33(11): 1012-1018.
31. Ishida A, Tanaka H, Hiura T, et al. Generation of anti-tumour effector T cells from naïve T cells by stimulation with dendritic/tumour fusion cells. Scand J Immunol. 2007;66(5):546-554. (Pubitemid 47609703)
32. Guo GH, Chen SZ, Yu J, et al. In vivo anti-tumor effect of hybrid vaccine of dendritic cells and esophageal carcinoma cells on esophageal carcinoma cell line 109 in mice with severe combined immune deficiency. World J Gastroenterol. 2008;14(8):1167-1174.
33. Li Y, Huang SL, Zhang XC, et al. The cytotoxicity of CIK/NK cells stimulated by K562-DC fusion vaccines in NOD/SCID mice model for human erythroleukemia. Zhonghua Xue Ye Xue Za Zhi. 2008; 29(1):39-43.
34. Zhang M, Berndt BE, Chen JJ, et al. Expression of a soluble TGF-beta receptor by tumor cells enhances dendritic cell/tumor fusion vaccine efficacy. J Immunol. 2008;181(5):3690-3697.
35. Ziske C, Tiemann K, Schmidt T, et al. Real-time compound imaging allows percutaneous initiation and surveillance in an orthotopic murine pancreatic cancer model. Pancreas. 2008;36(2): 146-152.
36. Trefzer U, Weingart G, Chen Y, et al. Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. Int J Cancer. 2000;85:618-626. (Pubitemid 30080472)
37. Kikuchi T, Akasaki Y, Irie M, et al. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother. 2001;50: 337-344. (Pubitemid 32835343)
38. Kikuchi T, Moore MA, Crystal RG. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood. 2000;96(1):91-99. (Pubitemid 30456456)
39. Kikuchi T, Worgall S, Singh R, et al. Dendritic cells genetically modified to express CD40 ligand and pulsed with antigen can initiate antigen-specific humoral immunity independent of CD4+ T cells. Nat Med. 2000;6(10):1154-1159. (Pubitemid 30792196)